| Title |
Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
|
|---|---|
| Published in |
Advances in Therapy, June 2014
|
| DOI | 10.1007/s12325-014-0126-8 |
| Pubmed ID | |
| Authors |
Takashi Kadowaki, Masakazu Haneda, Nobuya Inagaki, Yasuo Terauchi, Atsushi Taniguchi, Kazuki Koiwai, Henning Rattunde, Hans J. Woerle, Uli C. Broedl |
| Abstract |
This study was designed to determine the efficacy and tolerability of empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus (T2DM). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 100 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 17 | 17% |
| Student > Master | 13 | 13% |
| Other | 10 | 10% |
| Student > Ph. D. Student | 8 | 8% |
| Student > Doctoral Student | 5 | 5% |
| Other | 13 | 13% |
| Unknown | 34 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 32% |
| Biochemistry, Genetics and Molecular Biology | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 7% |
| Nursing and Health Professions | 5 | 5% |
| Agricultural and Biological Sciences | 2 | 2% |
| Other | 12 | 12% |
| Unknown | 35 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2014.
All research outputs
#15,308,698
of 22,768,097 outputs
Outputs from Advances in Therapy
#1,291
of 2,337 outputs
Outputs of similar age
#133,736
of 228,119 outputs
Outputs of similar age from Advances in Therapy
#11
of 21 outputs
Altmetric has tracked 22,768,097 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,337 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,119 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.